Tenax Therapeutics, Inc.
TENX· Nasdaq
Filed Nov 13, 2023 · 10-Q · 44 days after period end · 0001654954-23-014168
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Net Income | $1.97M | $2.92M | $3.80M | -$2.22M |
| EPS Diluted | — | — | -$0.15 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end